{"gene":"PPARA","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1995,"finding":"PPARα (PPAR) forms a heterodimer with retinoid X receptor (RXR) and binds to specific DNA sequences (peroxisome proliferator response elements) upstream of peroxisome proliferator-responsive genes, mediating transcriptional activation.","method":"Transcriptional transactivation assay, DNA binding studies","journal":"Mutation research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — DNA binding and transactivation demonstrated, replicated across multiple labs in this era","pmids":["8538617"],"is_preprint":false},{"year":1995,"finding":"Fatty acids (arachidonic acid, linoleic acid, and saturated fatty acids of sufficient chain length) directly activate PPARα in a transcriptional transactivation assay; beta-oxidation is not required for formation of the PPAR-activating molecule, suggesting the active ligand is a fatty acid, its CoA ester, or a derivative prior to beta-oxidation.","method":"Stable CHO cell transcriptional transactivation assay using PPAR-glucocorticoid receptor chimera with MMTV-PLAP reporter; metabolic inhibitor studies","journal":"The Journal of steroid biochemistry and molecular biology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — reconstituted cell-based assay with systematic fatty acid structure-activity, single lab","pmids":["7626496"],"is_preprint":false},{"year":1995,"finding":"Human NUC1 (a PPAR subtype, PPARβ/δ) acts as a repressor of hPPARα transcriptional activation; hNUC1 cooperatively binds a PPAR-responsive element with hRXRα and represses hPPARα by titrating out a factor required for activation. Repression is specific (does not affect progesterone or retinoic acid receptors) and is overcome by excess hPPARα.","method":"Transient transfection reporter assay, co-operative DNA binding assay, competitive transfection","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal functional assays with specificity controls, single lab","pmids":["7876127"],"is_preprint":false},{"year":2000,"finding":"PPARα activation downregulates hepatic apolipoprotein C-III gene expression and increases lipoprotein lipase gene expression, providing the molecular basis for fibrate-induced triglyceride lowering. PPARα also induces apolipoprotein A-I and A-II expression in humans to raise HDL cholesterol.","method":"Gene expression assays in hepatic and other cell systems; fibrate treatment studies","journal":"Clinical chemistry and laboratory medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gene regulation demonstrated across multiple target genes, replicated in multiple studies referenced","pmids":["10774955"],"is_preprint":false},{"year":2003,"finding":"PPARα negatively interferes with inflammatory gene expression by upregulating the cytoplasmic inhibitor IκBα, establishing an autoregulatory loop with NF-κB. This induction occurs in the absence of a PPRE but requires NF-κB and Sp1 elements in the IκBα promoter and DRIP250 cofactors.","method":"Promoter reporter assays, cofactor requirement analysis","journal":"Advances in experimental medicine and biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter analysis with defined element requirements, single lab but multiple methods described","pmids":["14713228"],"is_preprint":false},{"year":2006,"finding":"Ppara knockout mice and siRNA-mediated hepatic Ppara knockdown produce comparable transcriptional profiles and metabolic phenotypes (hypoglycemia, hypertriglyceridemia), validating that these phenotypes are specifically due to loss of PPARα function in the liver. Combined with fenofibrate agonist profiles, candidate genes proximal to PPARα regulation were identified.","method":"Genetic knockout comparison, hydrodynamic siRNA delivery, transcriptional profiling, metabolic phenotyping","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO and RNAi knockdown with identical phenotypes, multiple orthogonal methods","pmids":["16945951"],"is_preprint":false},{"year":2007,"finding":"AMPK activators (AICAR and metformin) inhibit PPARα (and PPARγ) transcriptional activity in hepatoma cells; this inhibition does not affect PPAR/RXR binding to DNA and does not depend on AMPK kinase activity but rather on the activated conformation of AMPK.","method":"Transfection with PPRE luciferase reporter, AMPK activator/inhibitor treatment, EMSA for DNA binding, nuclear localization studies","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (reporter assay, DNA binding, dominant-negative/constitutively active constructs), single lab","pmids":["21700905"],"is_preprint":false},{"year":2012,"finding":"PPARα (PPARA) transcriptionally regulates CYP3A4 expression in human liver; shRNA-mediated PPARA knockdown in primary human hepatocytes decreased CYP3A4 mRNA by more than 50%, and PPARA SNP rs4253728 associates with reduced PPAR-α protein and reduced CYP3A4 activity in a human liver bank.","method":"shRNA knockdown in primary human hepatocytes, candidate-gene association in human liver bank, pharmacokinetic validation in atorvastatin-treated volunteers","journal":"Clinical pharmacology and therapeutics","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional knockdown in primary cells plus human genetic validation and pharmacokinetic confirmation, multiple orthogonal methods","pmids":["22510778"],"is_preprint":false},{"year":2015,"finding":"Krüppel-like factor 5 (KLF5) activates Ppara gene expression via direct binding to the Ppara promoter in cardiac myocytes; this is blocked in septic mouse hearts by c-Jun, which binds an overlapping promoter site. Cardiac-specific Klf5 knockout mice show reduced Ppara expression, reduced fatty acid oxidation, decreased ATP, increased triglyceride accumulation, and cardiac dysfunction.","method":"Promoter binding assay (direct binding), cardiac-specific conditional knockout mice, metabolic flux measurements, echocardiography","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct promoter binding demonstrated, conditional KO with defined metabolic and functional phenotype, multiple orthogonal methods","pmids":["26574507"],"is_preprint":false},{"year":2017,"finding":"Hepatocyte-specific PPARA is exclusively responsible for agonist-induced hepatocyte proliferation; macrophage PPARA does not contribute to proliferation but is required for downregulation of inflammatory cytokines IL-15 and IL-18 in response to PPARA agonism.","method":"Hepatocyte-specific and macrophage-specific conditional Ppara knockout mice, Wy-14643 agonist treatment, BrdU labeling, gene expression analysis, primary cell studies","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional knockouts with defined phenotypic readouts, multiple orthogonal methods","pmids":["28082284"],"is_preprint":false},{"year":2019,"finding":"Pharmacological activation of PPARA by agonists gemfibrozil or Wy14643 induces autophagy in human microglia and glioma cells in a PPARA-dependent manner (shown by siRNA knockdown), leading to enhanced autophagosome biogenesis, reduced soluble and insoluble Aβ, and reversal of memory deficits in APP-PSEN1ΔE9 mice.","method":"PPARA agonist treatment, siRNA knockdown, autophagy marker analysis (LC3B, SQSTM1), ELISA for Aβ, behavioral testing in transgenic mice","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic (siRNA) approaches, multiple readouts, single lab","pmids":["30898012"],"is_preprint":false},{"year":2018,"finding":"PPARA activation facilitates primary ciliogenesis by promoting autophagy; pharmacological or genetic inactivation of autophagy blocks PPARA-induced ciliogenesis. Conversely, NR1H4/FXR activation represses cilia formation. In ppara-/- mice, starvation-induced ciliogenesis is impaired due to defective autophagy, and kidneys show ciliopathy-like damage.","method":"PPARA agonist/antagonist treatment, ppara-/- mice, genetic autophagy knockdown, rapamycin rescue, NR1H4 knockdown, in vivo starvation studies","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO mouse model plus pharmacological and genetic manipulation in vitro with multiple orthogonal readouts, in vivo validation","pmids":["29771182"],"is_preprint":false},{"year":2019,"finding":"Lysosomal inhibition downregulates PPARA and its coactivator PPARGC1A/PGC1α at the transcriptional level, suppressing peroxisomal gene expression; ectopic induction of PPARA transcriptional activity rescues peroxisomal gene expression after lysosomal inhibition.","method":"Bafilomycin A1 treatment, TFEB knockdown, microarray and qPCR, PPARA overexpression rescue in AML12 hepatocyte cell line","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic manipulation with rescue experiment, single lab","pmids":["31032705"],"is_preprint":false},{"year":2020,"finding":"PPARα directly upregulates the long non-coding RNA gene Gm15441 through PPARα binding sites within its promoter; Gm15441 expression suppresses its antisense transcript encoding TXNIP, which in turn decreases TXNIP-stimulated NLRP3 inflammasome activation, CASP1 cleavage, and IL1B maturation. Gm15441-null mice show elevated NLRP3 inflammasome activation in response to PPARα agonism and fasting.","method":"ChIP for PPARα binding sites, Gm15441-null mouse generation, inflammasome activation assays, CASP1/IL1B cleavage analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct PPARα binding at promoter demonstrated by ChIP, genetic null mouse validation, multiple pathway readouts","pmids":["33203882"],"is_preprint":false},{"year":2022,"finding":"PPARA activation promotes hepatocyte proliferation via an epigenetic mechanism: PPARA induces E2F8 expression (a newly identified PPARA target gene), which upregulates UHRF1, which then methylates the Cdh1 promoter (marked with H3K9me3) to repress CDH1 expression and activate Wnt/Myc signaling driving hyperproliferation.","method":"PPARA agonist treatment, PPARA-deficient mice, E2F8/UHRF1 knockdown, ChIP for H3K9me3 at Cdh1 promoter, CDH1 forced expression, Wnt target gene analysis","journal":"iScience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic interventions, ChIP demonstrating epigenetic mark, rescue/forced expression experiments establishing pathway order","pmids":["35479397"],"is_preprint":false},{"year":2012,"finding":"miR-141 suppresses HBV replication by targeting PPARA at the post-transcriptional level; siRNA knockdown of PPARA inhibits HBV replication similarly to miR-141, and the mechanism involves interference with HBV promoter function through reduced PPARA activity.","method":"miRNA mimic transfection, siRNA knockdown of PPARA, luciferase promoter reporter assay, HBV replication quantification in HepG2 cells","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA and miRNA mimic with promoter reporter validation, single lab","pmids":["22479552"],"is_preprint":false},{"year":2021,"finding":"MIR20B specifically targets PPARA mRNA, reducing fatty acid oxidation and mitochondrial biogenesis in hepatocytes; MIR20B overexpression increases hepatic lipid accumulation and suppresses the therapeutic effect of fenofibrate (PPARα agonist) in NAFLD mouse models, while anti-MIR20B improves FA oxidation and insulin sensitivity.","method":"miRNA regulatory network analysis, MIR20B mimic/anti-MIR20B in HepG2, Huh-7, primary hepatocytes and HFD/MCD mice, luciferase reporter, FA oxidation assay, mitochondrial biogenesis measurement","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — validated in multiple cell types and in vivo mouse models with mechanistic rescue experiments, multiple orthogonal methods","pmids":["34964438"],"is_preprint":false},{"year":2009,"finding":"PPARA-null mice develop age-related hepatic steatosis, with reductions in glucose and glycogen in liver and muscle and profound changes in lipid metabolism across tissues, demonstrating that PPARA is required for normal fatty acid and glucose homeostasis in liver, heart, skeletal muscle, and adipose tissue.","method":"1H NMR spectroscopy and GC-MS metabolomics in Ppara-null vs wild-type mice across aging (3–13 months), multivariate statistics","journal":"Molecular systems biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — metabolomic profiling of genetic KO across multiple tissues and timepoints, single study","pmids":["19357638"],"is_preprint":false}],"current_model":"PPARα (PPARA) is a ligand-activated nuclear receptor transcription factor that heterodimerizes with RXR to bind peroxisome proliferator response elements (PPREs) and directly regulate genes governing fatty acid uptake, beta-oxidation, lipoprotein metabolism (ApoA-I, ApoA-II, ApoC-III, LPL), and peroxisomal/mitochondrial lipid catabolism; it suppresses hepatic inflammation via IκBα upregulation, promotes autophagy to drive ciliogenesis and Aβ clearance, induces hepatocyte proliferation through an E2F8-UHRF1-CDH1 epigenetic axis, regulates CYP3A4 expression in hepatocytes, and is transcriptionally controlled by upstream factors including KLF5 (activator) and c-Jun (repressor) at its promoter, as well as post-transcriptionally by miRNAs (miR-141, miR-20b), while its activity is inhibited by AMPK in a kinase-activity-independent manner."},"narrative":{"mechanistic_narrative":"PPARα (PPARA) is a ligand-activated nuclear receptor that heterodimerizes with retinoid X receptor (RXR) and binds peroxisome proliferator response elements (PPREs) upstream of target genes to drive transcription, with fatty acids and their derivatives serving as direct activating ligands [PMID:8538617, PMID:7626496]. Through this activity it is the master transcriptional regulator of hepatic and systemic lipid handling: it lowers triglycerides by repressing apolipoprotein C-III and inducing lipoprotein lipase, raises HDL via ApoA-I/ApoA-II induction [PMID:10774955], and is required for normal fatty acid and glucose homeostasis across liver, heart, muscle, and adipose tissue, with loss producing hepatic steatosis, hypoglycemia, and hypertriglyceridemia [PMID:16945951, PMID:19357638]. PPARα additionally restrains inflammation through PPRE-independent transcriptional outputs, upregulating IκBα to form an autoregulatory loop with NF-κB [PMID:14713228] and inducing the lncRNA Gm15441 to suppress TXNIP-driven NLRP3 inflammasome activation [PMID:33203882]. It promotes autophagy, which underlies PPARα-dependent primary ciliogenesis and Aβ clearance [PMID:29771182, PMID:30898012], and it drives hepatocyte proliferation in a hepatocyte-autonomous manner through an E2F8–UHRF1–CDH1 epigenetic axis activating Wnt/Myc signaling [PMID:28082284, PMID:35479397]. In human liver it also regulates CYP3A4 expression [PMID:22510778]. PPARA expression and activity are controlled by upstream transcription factors KLF5 (activator) and c-Jun (repressor) at its promoter [PMID:26574507], by miRNAs miR-141 and miR-20b post-transcriptionally [PMID:22479552, PMID:34964438], and its transactivation is inhibited by activated AMPK independently of AMPK kinase activity and without altering DNA binding [PMID:21700905].","teleology":[{"year":1995,"claim":"Established the core molecular machinery: how PPARα converts a signal into transcription by defining its DNA target, dimerization partner, and the nature of its activating ligand.","evidence":"Transactivation and DNA-binding assays showing RXR heterodimerization at PPREs; CHO chimera reporter assays mapping fatty-acid structure-activity","pmids":["8538617","7626496"],"confidence":"High","gaps":["Endogenous physiological ligand identity not resolved","Co-activator/co-repressor recruitment not detailed"]},{"year":1995,"claim":"Showed PPARα activity is constrained by competition within the receptor family, identifying NUC1 (PPARβ/δ) as a repressor titrating a shared limiting factor.","evidence":"Transient transfection reporter and cooperative DNA-binding assays with receptor specificity controls","pmids":["7876127"],"confidence":"Medium","gaps":["Identity of the titrated activating factor not determined","In vivo relevance of the repression not tested"]},{"year":2000,"claim":"Connected PPARα transcriptional outputs to clinically relevant lipoprotein metabolism, providing the mechanistic basis for fibrate triglyceride lowering and HDL raising.","evidence":"Gene expression assays for ApoC-III, LPL, ApoA-I/A-II under fibrate treatment in hepatic systems","pmids":["10774955"],"confidence":"Medium","gaps":["Direct vs indirect regulation of each target not fully dissected","Human in vivo confirmation limited"]},{"year":2003,"claim":"Defined a PPRE-independent anti-inflammatory mechanism, showing PPARα enforces an autoregulatory brake on NF-κB via IκBα induction.","evidence":"Promoter reporter assays with NF-κB/Sp1 element and DRIP250 cofactor requirement analysis","pmids":["14713228"],"confidence":"Medium","gaps":["Mechanism of cofactor-dependent activation without a PPRE unclear","Single-lab promoter analysis"]},{"year":2006,"claim":"Validated that hepatic loss-of-function phenotypes are specifically attributable to PPARα, distinguishing on-target effects from genetic compensation.","evidence":"Comparison of Ppara knockout vs hepatic siRNA knockdown with transcriptional profiling and metabolic phenotyping","pmids":["16945951"],"confidence":"High","gaps":["Direct target genes not separated from secondary responses"]},{"year":2007,"claim":"Identified an unexpected non-canonical inhibition of PPARα by AMPK acting through its activated conformation rather than kinase activity.","evidence":"PPRE luciferase reporter, EMSA, and dominant-negative/constitutively active AMPK constructs in hepatoma cells","pmids":["21700905"],"confidence":"Medium","gaps":["Physical basis of conformation-dependent inhibition not resolved","In vivo significance untested"]},{"year":2009,"claim":"Demonstrated PPARα is required systemically for lipid and glucose homeostasis across multiple tissues, not just liver.","evidence":"1H NMR and GC-MS metabolomics in Ppara-null vs wild-type mice across aging and tissues","pmids":["19357638"],"confidence":"Medium","gaps":["Tissue-specific contributions not separated","Causal target genes not identified"]},{"year":2012,"claim":"Extended PPARα function into xenobiotic metabolism and provided human genetic validation of its control of CYP3A4.","evidence":"shRNA knockdown in primary human hepatocytes, SNP association in a liver bank, and pharmacokinetic confirmation in volunteers","pmids":["22510778"],"confidence":"High","gaps":["Direct binding at CYP3A4 regulatory regions not shown","Mechanism of SNP effect on protein level unclear"]},{"year":2012,"claim":"Showed PPARA is a post-transcriptional target whose suppression affects viral biology, linking miR-141-mediated PPARA reduction to HBV replication control.","evidence":"miRNA mimic and PPARA siRNA with luciferase promoter reporter and HBV replication quantification in HepG2","pmids":["22479552"],"confidence":"Medium","gaps":["Mechanism by which PPARA supports HBV promoter function not defined","In vivo relevance untested"]},{"year":2015,"claim":"Identified the upstream transcriptional control of PPARA itself, with KLF5 activating and c-Jun repressing the promoter to govern cardiac fatty acid oxidation.","evidence":"Direct promoter binding assays, cardiac-specific Klf5 conditional knockout, metabolic flux and echocardiography","pmids":["26574507"],"confidence":"High","gaps":["Generalization beyond cardiomyocytes not established","Other promoter regulators not mapped"]},{"year":2017,"claim":"Dissected cell-type-specific PPARα roles, showing hepatocyte PPARα drives proliferation while macrophage PPARα controls inflammatory cytokine suppression.","evidence":"Hepatocyte- and macrophage-specific conditional Ppara knockouts with Wy-14643, BrdU labeling and cytokine analysis","pmids":["28082284"],"confidence":"High","gaps":["Molecular mediators of proliferation not yet defined at this stage"]},{"year":2018,"claim":"Linked PPARα to autophagy-dependent organelle biogenesis, establishing that PPARα-driven autophagy is required for primary ciliogenesis.","evidence":"PPARA agonist/antagonist, ppara-/- mice, autophagy knockdown, rapamycin rescue, and starvation studies","pmids":["29771182"],"confidence":"High","gaps":["Direct autophagy gene targets of PPARα not enumerated","Mechanism opposing FXR repression unclear"]},{"year":2019,"claim":"Generalized PPARα-driven autophagy to neurodegeneration, showing agonist-induced autophagy enhances Aβ clearance and reverses memory deficits.","evidence":"Agonist treatment with siRNA knockdown, autophagy markers, Aβ ELISA, and behavior in APP-PSEN1ΔE9 mice","pmids":["30898012"],"confidence":"Medium","gaps":["Direct transcriptional targets driving autophagosome biogenesis unspecified","Single-lab finding"]},{"year":2019,"claim":"Revealed a lysosome-to-nucleus feedback whereby lysosomal function sustains PPARA/PGC1α transcription to maintain peroxisomal gene expression.","evidence":"Bafilomycin A1, TFEB knockdown, microarray/qPCR, and PPARA overexpression rescue in AML12 cells","pmids":["31032705"],"confidence":"Medium","gaps":["Mechanism by which lysosomal status controls PPARA transcription unclear","In vivo confirmation lacking"]},{"year":2020,"claim":"Defined a direct PPARα-driven lncRNA circuit (Gm15441) that restrains the TXNIP–NLRP3 inflammasome during agonism and fasting.","evidence":"ChIP for PPARα binding sites, Gm15441-null mice, and inflammasome/CASP1/IL1B readouts","pmids":["33203882"],"confidence":"High","gaps":["Human orthologous lncRNA mechanism not addressed"]},{"year":2021,"claim":"Established MIR20B as a post-transcriptional repressor of PPARA controlling hepatic fatty acid oxidation and fibrate response in NAFLD.","evidence":"MIR20B mimic/anti-MIR20B in multiple hepatocyte lines and HFD/MCD mice, luciferase reporter, FA oxidation and mitochondrial biogenesis assays","pmids":["34964438"],"confidence":"High","gaps":["Interplay with other PPARA-targeting miRNAs not resolved"]},{"year":2022,"claim":"Resolved the molecular mediators of hepatocyte proliferation, defining the E2F8–UHRF1–CDH1 epigenetic axis downstream of PPARα.","evidence":"Agonist treatment, PPARA-deficient mice, E2F8/UHRF1 knockdown, ChIP for H3K9me3 at Cdh1, CDH1 forced expression, Wnt target analysis","pmids":["35479397"],"confidence":"High","gaps":["Direct vs indirect PPARα regulation of E2F8 not fully shown","Relevance to human hepatocarcinogenesis untested"]},{"year":null,"claim":"The endogenous physiological ligand of PPARα and the structural basis of its non-canonical regulation (AMPK conformation, PPRE-independent transactivation) remain undefined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No defined endogenous activating ligand","No structural model linking AMPK conformation to PPARα inhibition","Cofactor logic of PPRE-independent gene induction unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,3,13,14]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,13]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[1]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,6]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,5,16,17]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,13,14]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,13,9]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[10,11,12]}],"complexes":["PPARα-RXR heterodimer"],"partners":["RXR","KLF5","JUN","PPARGC1A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q07869","full_name":"Peroxisome proliferator-activated receptor alpha","aliases":["Nuclear receptor subfamily 1 group C member 1"],"length_aa":468,"mass_kda":52.2,"function":"Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as a transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to metabolic pathways regulated by PER2","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q07869/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PPARA","classification":"Not Classified","n_dependent_lines":5,"n_total_lines":1208,"dependency_fraction":0.0041390728476821195},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PPARA","total_profiled":1310},"omim":[{"mim_id":"618216","title":"MIRLET7B HOST GENE, NONCODING; MIRLET7BHG","url":"https://www.omim.org/entry/618216"},{"mim_id":"617905","title":"HYPOXIA-INDUCIBLE LIPID DROPLET-ASSOCIATED PROTEIN; HILPDA","url":"https://www.omim.org/entry/617905"},{"mim_id":"617870","title":"CENTROSOMAL PROTEIN 350; CEP350","url":"https://www.omim.org/entry/617870"},{"mim_id":"617382","title":"START DOMAIN-CONTAINING PROTEIN 10; STARD10","url":"https://www.omim.org/entry/617382"},{"mim_id":"616936","title":"CHROMODOMAIN HELICASE DNA-BINDING PROTEIN 9; CHD9","url":"https://www.omim.org/entry/616936"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Primary cilium","reliability":"Uncertain"},{"location":"Nucleoli fibrillar center","reliability":"Additional"},{"location":"Nuclear bodies","reliability":"Additional"},{"location":"Centriolar satellite","reliability":"Additional"},{"location":"Basal body","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"tongue","ntpm":39.7}],"url":"https://www.proteinatlas.org/search/PPARA"},"hgnc":{"alias_symbol":["hPPAR","NR1C1"],"prev_symbol":["PPAR"]},"alphafold":{"accession":"Q07869","domains":[{"cath_id":"3.30.50.10","chopping":"110-174","consensus_level":"high","plddt":93.9172,"start":110,"end":174},{"cath_id":"1.10.565.10","chopping":"199-463","consensus_level":"high","plddt":93.8097,"start":199,"end":463}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07869","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q07869-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q07869-F1-predicted_aligned_error_v6.png","plddt_mean":80.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PPARA","jax_strain_url":"https://www.jax.org/strain/search?query=PPARA"},"sequence":{"accession":"Q07869","fasta_url":"https://rest.uniprot.org/uniprotkb/Q07869.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q07869/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07869"}},"corpus_meta":[{"pmid":"9568680","id":"PMC_9568680","title":"PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.","date":"1998","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/9568680","citation_count":1484,"is_preprint":false},{"pmid":"34127848","id":"PMC_34127848","title":"PPAR control of metabolism and cardiovascular functions.","date":"2021","source":"Nature reviews. Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/34127848","citation_count":751,"is_preprint":false},{"pmid":"16511590","id":"PMC_16511590","title":"PPAR gamma and human metabolic disease.","date":"2006","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16511590","citation_count":655,"is_preprint":false},{"pmid":"25450819","id":"PMC_25450819","title":"PPAR gamma gene--a review.","date":"2014","source":"Diabetes & metabolic syndrome","url":"https://pubmed.ncbi.nlm.nih.gov/25450819","citation_count":559,"is_preprint":false},{"pmid":"32791172","id":"PMC_32791172","title":"The role of peroxisome proliferator-activated receptors (PPAR) in immune responses.","date":"2020","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/32791172","citation_count":534,"is_preprint":false},{"pmid":"9425261","id":"PMC_9425261","title":"Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9425261","citation_count":429,"is_preprint":false},{"pmid":"27077495","id":"PMC_27077495","title":"An update on PPAR activation by cannabinoids.","date":"2016","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27077495","citation_count":367,"is_preprint":false},{"pmid":"12055342","id":"PMC_12055342","title":"PPAR(gamma) and glucose homeostasis.","date":"2002","source":"Annual review of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/12055342","citation_count":361,"is_preprint":false},{"pmid":"17560826","id":"PMC_17560826","title":"Modulation of PPAR activity via phosphorylation.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17560826","citation_count":361,"is_preprint":false},{"pmid":"30898012","id":"PMC_30898012","title":"Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model.","date":"2019","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/30898012","citation_count":308,"is_preprint":false},{"pmid":"15489539","id":"PMC_15489539","title":"PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/15489539","citation_count":271,"is_preprint":false},{"pmid":"18323516","id":"PMC_18323516","title":"Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men.","date":"2008","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18323516","citation_count":254,"is_preprint":false},{"pmid":"26632493","id":"PMC_26632493","title":"Fatty acids, eicosanoids and PPAR gamma.","date":"2015","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26632493","citation_count":241,"is_preprint":false},{"pmid":"15925327","id":"PMC_15925327","title":"Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?","date":"2005","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15925327","citation_count":241,"is_preprint":false},{"pmid":"11042466","id":"PMC_11042466","title":"PPAR gamma and the treatment of insulin resistance.","date":"2000","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/11042466","citation_count":241,"is_preprint":false},{"pmid":"10774955","id":"PMC_10774955","title":"Regulation of lipid and lipoprotein metabolism by PPAR activators.","date":"2000","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10774955","citation_count":216,"is_preprint":false},{"pmid":"28581362","id":"PMC_28581362","title":"PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.","date":"2017","source":"Future cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/28581362","citation_count":207,"is_preprint":false},{"pmid":"16322072","id":"PMC_16322072","title":"The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR).","date":"2005","source":"Toxicological sciences : an official journal of the Society of Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/16322072","citation_count":206,"is_preprint":false},{"pmid":"18782619","id":"PMC_18782619","title":"Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors.","date":"2008","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/18782619","citation_count":190,"is_preprint":false},{"pmid":"8651933","id":"PMC_8651933","title":"Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa.","date":"1996","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8651933","citation_count":187,"is_preprint":false},{"pmid":"14713228","id":"PMC_14713228","title":"A paradigm for gene regulation: inflammation, NF-kappaB and PPAR.","date":"2003","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/14713228","citation_count":186,"is_preprint":false},{"pmid":"18996469","id":"PMC_18996469","title":"Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development.","date":"2008","source":"Reproductive toxicology (Elmsford, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18996469","citation_count":174,"is_preprint":false},{"pmid":"17010956","id":"PMC_17010956","title":"The PPAR regulatory system in cardiac physiology and disease.","date":"2006","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/17010956","citation_count":173,"is_preprint":false},{"pmid":"11007963","id":"PMC_11007963","title":"Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.","date":"2000","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11007963","citation_count":167,"is_preprint":false},{"pmid":"35752307","id":"PMC_35752307","title":"In vitro activity of a panel of per- and polyfluoroalkyl substances (PFAS), fatty acids, and pharmaceuticals in peroxisome proliferator-activated receptor (PPAR) alpha, PPAR gamma, and estrogen receptor assays.","date":"2022","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35752307","citation_count":151,"is_preprint":false},{"pmid":"17416424","id":"PMC_17416424","title":"PPAR-gamma: therapeutic target for ischemic stroke.","date":"2007","source":"Trends in pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17416424","citation_count":151,"is_preprint":false},{"pmid":"18547997","id":"PMC_18547997","title":"Klotho is a target gene of PPAR-gamma.","date":"2008","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/18547997","citation_count":147,"is_preprint":false},{"pmid":"8538617","id":"PMC_8538617","title":"PPAR: a mediator of peroxisome proliferator action.","date":"1995","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/8538617","citation_count":146,"is_preprint":false},{"pmid":"18220654","id":"PMC_18220654","title":"Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.","date":"2007","source":"Current diabetes reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18220654","citation_count":143,"is_preprint":false},{"pmid":"25148456","id":"PMC_25148456","title":"Minireview: Challenges and opportunities in development of PPAR agonists.","date":"2014","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/25148456","citation_count":135,"is_preprint":false},{"pmid":"7626496","id":"PMC_7626496","title":"Fatty acid activation of peroxisome proliferator-activated receptor (PPAR).","date":"1995","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7626496","citation_count":124,"is_preprint":false},{"pmid":"22510778","id":"PMC_22510778","title":"PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.","date":"2012","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/22510778","citation_count":121,"is_preprint":false},{"pmid":"28330809","id":"PMC_28330809","title":"Piperine Attenuates Pathological Cardiac Fibrosis Via PPAR-γ/AKT Pathways.","date":"2017","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/28330809","citation_count":120,"is_preprint":false},{"pmid":"11902671","id":"PMC_11902671","title":"PPAR expression and function during vertebrate development.","date":"2002","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/11902671","citation_count":117,"is_preprint":false},{"pmid":"21700905","id":"PMC_21700905","title":"Activated AMPK inhibits PPAR-{alpha} and PPAR-{gamma} transcriptional activity in hepatoma cells.","date":"2011","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21700905","citation_count":110,"is_preprint":false},{"pmid":"9209705","id":"PMC_9209705","title":"PPAR gamma and the control of adipogenesis.","date":"1997","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/9209705","citation_count":109,"is_preprint":false},{"pmid":"24658827","id":"PMC_24658827","title":"The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.","date":"2014","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24658827","citation_count":108,"is_preprint":false},{"pmid":"17457378","id":"PMC_17457378","title":"PPAR-gamma agonist protects podocytes from injury.","date":"2007","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/17457378","citation_count":105,"is_preprint":false},{"pmid":"32375405","id":"PMC_32375405","title":"PPAR Beta/Delta and the Hallmarks of Cancer.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32375405","citation_count":104,"is_preprint":false},{"pmid":"26574507","id":"PMC_26574507","title":"Cardiac Myocyte KLF5 Regulates Ppara Expression and Cardiac Function.","date":"2015","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/26574507","citation_count":101,"is_preprint":false},{"pmid":"16945951","id":"PMC_16945951","title":"Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice.","date":"2006","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16945951","citation_count":95,"is_preprint":false},{"pmid":"12349941","id":"PMC_12349941","title":"PPAR and immune system--what do we know?","date":"2002","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12349941","citation_count":90,"is_preprint":false},{"pmid":"33467433","id":"PMC_33467433","title":"PPAR Gamma: From Definition to Molecular Targets and Therapy of Lung Diseases.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33467433","citation_count":88,"is_preprint":false},{"pmid":"22479552","id":"PMC_22479552","title":"MicroRNA-141 represses HBV replication by targeting PPARA.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22479552","citation_count":88,"is_preprint":false},{"pmid":"32028670","id":"PMC_32028670","title":"PPAR-Mediated Toxicology and Applied Pharmacology.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32028670","citation_count":85,"is_preprint":false},{"pmid":"16574314","id":"PMC_16574314","title":"The pleiotropic function of PPAR gamma in the placenta.","date":"2006","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16574314","citation_count":84,"is_preprint":false},{"pmid":"7876127","id":"PMC_7876127","title":"The human peroxisome proliferator-activated receptor (PPAR) subtype NUC1 represses the activation of hPPAR alpha and thyroid hormone receptors.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7876127","citation_count":80,"is_preprint":false},{"pmid":"24315978","id":"PMC_24315978","title":"Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation.","date":"2013","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/24315978","citation_count":79,"is_preprint":false},{"pmid":"28082284","id":"PMC_28082284","title":"Hepatocyte-specific PPARA expression exclusively promotes agonist-induced cell proliferation without influence from nonparenchymal cells.","date":"2017","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28082284","citation_count":79,"is_preprint":false},{"pmid":"15910175","id":"PMC_15910175","title":"PPAR-alpha and insulin sensitivity.","date":"2005","source":"Physiological research","url":"https://pubmed.ncbi.nlm.nih.gov/15910175","citation_count":78,"is_preprint":false},{"pmid":"34697644","id":"PMC_34697644","title":"The Role of PPAR-γ in Allergic Disease.","date":"2021","source":"Current allergy and asthma reports","url":"https://pubmed.ncbi.nlm.nih.gov/34697644","citation_count":75,"is_preprint":false},{"pmid":"9168928","id":"PMC_9168928","title":"Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9168928","citation_count":71,"is_preprint":false},{"pmid":"28095188","id":"PMC_28095188","title":"miR-148a and miR-17-5p synergistically regulate milk TAG synthesis via PPARGC1A and PPARA in goat mammary epithelial cells.","date":"2017","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/28095188","citation_count":70,"is_preprint":false},{"pmid":"30012954","id":"PMC_30012954","title":"Maintenance of Kidney Metabolic Homeostasis by PPAR Gamma.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30012954","citation_count":67,"is_preprint":false},{"pmid":"19357638","id":"PMC_19357638","title":"Metabolomics of the interaction between PPAR-alpha and age in the PPAR-alpha-null mouse.","date":"2009","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/19357638","citation_count":66,"is_preprint":false},{"pmid":"22471957","id":"PMC_22471957","title":"PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations.","date":"2012","source":"Cardiovascular & hematological agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22471957","citation_count":66,"is_preprint":false},{"pmid":"33203882","id":"PMC_33203882","title":"Long non-coding RNA Gm15441 attenuates hepatic inflammasome activation in response to PPARA agonism and fasting.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33203882","citation_count":66,"is_preprint":false},{"pmid":"12505304","id":"PMC_12505304","title":"PPAR alpha and the regulation of cell division and apoptosis.","date":"2002","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/12505304","citation_count":62,"is_preprint":false},{"pmid":"15803109","id":"PMC_15803109","title":"PPAR delta: an uncompletely known nuclear receptor.","date":"2005","source":"Diabetes & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15803109","citation_count":60,"is_preprint":false},{"pmid":"8168153","id":"PMC_8168153","title":"Peroxisome proliferator-activated receptor (PPAR): structure, mechanisms of activation and diverse functions.","date":"1993","source":"Cell structure and function","url":"https://pubmed.ncbi.nlm.nih.gov/8168153","citation_count":59,"is_preprint":false},{"pmid":"16005906","id":"PMC_16005906","title":"PPAR-gamma: a nuclear receptor with affinity for cannabinoids.","date":"2005","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16005906","citation_count":59,"is_preprint":false},{"pmid":"17611579","id":"PMC_17611579","title":"PPAR and LXR activators regulate ABCA12 expression in human keratinocytes.","date":"2007","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17611579","citation_count":59,"is_preprint":false},{"pmid":"35418650","id":"PMC_35418650","title":"CHD7 regulates bone-fat balance by suppressing PPAR-γ signaling.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35418650","citation_count":58,"is_preprint":false},{"pmid":"34964438","id":"PMC_34964438","title":"Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA.","date":"2021","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/34964438","citation_count":58,"is_preprint":false},{"pmid":"22697317","id":"PMC_22697317","title":"Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present).","date":"2012","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/22697317","citation_count":57,"is_preprint":false},{"pmid":"20828387","id":"PMC_20828387","title":"Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.","date":"2010","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/20828387","citation_count":57,"is_preprint":false},{"pmid":"18317435","id":"PMC_18317435","title":"Immunomodulatory role of PPAR-gamma in alveolar macrophages.","date":"2008","source":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","url":"https://pubmed.ncbi.nlm.nih.gov/18317435","citation_count":56,"is_preprint":false},{"pmid":"15673477","id":"PMC_15673477","title":"PPAR gamma as a metabolic regulator: insights from genomics and pharmacology.","date":"2005","source":"Expert reviews in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15673477","citation_count":55,"is_preprint":false},{"pmid":"32758586","id":"PMC_32758586","title":"Minutes of PPAR-γ agonism and neuroprotection.","date":"2020","source":"Neurochemistry international","url":"https://pubmed.ncbi.nlm.nih.gov/32758586","citation_count":52,"is_preprint":false},{"pmid":"12700342","id":"PMC_12700342","title":"PPAR(alpha) and PPAR(gamma) activators suppress the monocyte-macrophage apoB-48 receptor.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12700342","citation_count":52,"is_preprint":false},{"pmid":"30400386","id":"PMC_30400386","title":"Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30400386","citation_count":52,"is_preprint":false},{"pmid":"17069008","id":"PMC_17069008","title":"Functions of the peroxisome proliferator-activated receptor (PPAR) alpha and beta in skin homeostasis, epithelial repair, and morphogenesis.","date":"2006","source":"The journal of investigative dermatology. Symposium proceedings","url":"https://pubmed.ncbi.nlm.nih.gov/17069008","citation_count":52,"is_preprint":false},{"pmid":"21519405","id":"PMC_21519405","title":"PPAR-alpha in cutaneous inflammation.","date":"2011","source":"Dermato-endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21519405","citation_count":51,"is_preprint":false},{"pmid":"24128860","id":"PMC_24128860","title":"Activation of PPAR α and PPAR β/δ regulates Sertoli cell metabolism.","date":"2013","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24128860","citation_count":51,"is_preprint":false},{"pmid":"30031228","id":"PMC_30031228","title":"LAZ3 protects cardiac remodeling in diabetic cardiomyopathy via regulating miR-21/PPARa signaling.","date":"2018","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/30031228","citation_count":50,"is_preprint":false},{"pmid":"26072262","id":"PMC_26072262","title":"Peroxisome proliferator-activated receptor (PPAR) gamma in cardiovascular disorders and cardiovascular surgery.","date":"2015","source":"Journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/26072262","citation_count":50,"is_preprint":false},{"pmid":"18756295","id":"PMC_18756295","title":"PPAR-gamma and aging: one link through klotho?","date":"2008","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/18756295","citation_count":46,"is_preprint":false},{"pmid":"23059473","id":"PMC_23059473","title":"1,25-Dihydroxyvitamin D3 modulates lipid metabolism in prostate cancer cells through miRNA mediated regulation of PPARA.","date":"2012","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23059473","citation_count":43,"is_preprint":false},{"pmid":"21966330","id":"PMC_21966330","title":"Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators.","date":"2011","source":"The open medicinal chemistry journal","url":"https://pubmed.ncbi.nlm.nih.gov/21966330","citation_count":42,"is_preprint":false},{"pmid":"15726824","id":"PMC_15726824","title":"Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis.","date":"2004","source":"Lipids","url":"https://pubmed.ncbi.nlm.nih.gov/15726824","citation_count":41,"is_preprint":false},{"pmid":"38697298","id":"PMC_38697298","title":"MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists.","date":"2024","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/38697298","citation_count":41,"is_preprint":false},{"pmid":"31018521","id":"PMC_31018521","title":"Astaxanthin as a Peroxisome Proliferator-Activated Receptor (PPAR) Modulator: Its Therapeutic Implications.","date":"2019","source":"Marine drugs","url":"https://pubmed.ncbi.nlm.nih.gov/31018521","citation_count":41,"is_preprint":false},{"pmid":"17983557","id":"PMC_17983557","title":"PPAR agonists and the metabolic syndrome.","date":"2007","source":"Therapie","url":"https://pubmed.ncbi.nlm.nih.gov/17983557","citation_count":39,"is_preprint":false},{"pmid":"19607969","id":"PMC_19607969","title":"PPAR and Pain.","date":"2009","source":"International review of neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/19607969","citation_count":37,"is_preprint":false},{"pmid":"22731403","id":"PMC_22731403","title":"Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine.","date":"2012","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/22731403","citation_count":37,"is_preprint":false},{"pmid":"36768666","id":"PMC_36768666","title":"Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36768666","citation_count":36,"is_preprint":false},{"pmid":"17632033","id":"PMC_17632033","title":"Exploration of PPAR functions by microarray technology--a paradigm for nutrigenomics.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17632033","citation_count":36,"is_preprint":false},{"pmid":"36092543","id":"PMC_36092543","title":"Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments.","date":"2022","source":"PPAR research","url":"https://pubmed.ncbi.nlm.nih.gov/36092543","citation_count":35,"is_preprint":false},{"pmid":"14683520","id":"PMC_14683520","title":"PPAR ligands for metabolic disorders.","date":"2003","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14683520","citation_count":35,"is_preprint":false},{"pmid":"16411019","id":"PMC_16411019","title":"ACBP--a PPAR and SREBP modulated housekeeping gene.","date":"2006","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16411019","citation_count":35,"is_preprint":false},{"pmid":"29768688","id":"PMC_29768688","title":"PPAR-γ in innate and adaptive lung immunity.","date":"2018","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/29768688","citation_count":34,"is_preprint":false},{"pmid":"10022237","id":"PMC_10022237","title":"Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans.","date":"1998","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/10022237","citation_count":33,"is_preprint":false},{"pmid":"31480990","id":"PMC_31480990","title":"Long non-coding RNA LINC00467 regulates hepatocellular carcinoma progression by modulating miR-9-5p/PPARA expression.","date":"2019","source":"Open biology","url":"https://pubmed.ncbi.nlm.nih.gov/31480990","citation_count":32,"is_preprint":false},{"pmid":"31032705","id":"PMC_31032705","title":"Lysosomal inhibition attenuates peroxisomal gene transcription via suppression of PPARA and PPARGC1A levels.","date":"2019","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/31032705","citation_count":32,"is_preprint":false},{"pmid":"19132133","id":"PMC_19132133","title":"PPAR-delta in Vascular Pathophysiology.","date":"2009","source":"PPAR research","url":"https://pubmed.ncbi.nlm.nih.gov/19132133","citation_count":32,"is_preprint":false},{"pmid":"35479397","id":"PMC_35479397","title":"Gene repression through epigenetic modulation by PPARA enhances hepatocellular proliferation.","date":"2022","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/35479397","citation_count":31,"is_preprint":false},{"pmid":"36812713","id":"PMC_36812713","title":"The emerging role of PPAR-alpha in breast cancer.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36812713","citation_count":31,"is_preprint":false},{"pmid":"17277894","id":"PMC_17277894","title":"Peroxisome proliferator-activated receptor gamma (PPAR gamma) and sepsis.","date":"2007","source":"Archivum immunologiae et therapiae experimentalis","url":"https://pubmed.ncbi.nlm.nih.gov/17277894","citation_count":30,"is_preprint":false},{"pmid":"29771182","id":"PMC_29771182","title":"Ciliogenesis is reciprocally regulated by PPARA and NR1H4/FXR through controlling autophagy in vitro and in vivo.","date":"2018","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/29771182","citation_count":30,"is_preprint":false},{"pmid":"18221086","id":"PMC_18221086","title":"Role of PPAR in cardiovascular diseases.","date":"2006","source":"Recent patents on cardiovascular drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/18221086","citation_count":30,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44367,"output_tokens":4394,"usd":0.099505,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12680,"output_tokens":4728,"usd":0.0908,"stage2_stop_reason":"end_turn"},"total_usd":0.190305,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"PPARα (PPAR) forms a heterodimer with retinoid X receptor (RXR) and binds to specific DNA sequences (peroxisome proliferator response elements) upstream of peroxisome proliferator-responsive genes, mediating transcriptional activation.\",\n      \"method\": \"Transcriptional transactivation assay, DNA binding studies\",\n      \"journal\": \"Mutation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — DNA binding and transactivation demonstrated, replicated across multiple labs in this era\",\n      \"pmids\": [\"8538617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Fatty acids (arachidonic acid, linoleic acid, and saturated fatty acids of sufficient chain length) directly activate PPARα in a transcriptional transactivation assay; beta-oxidation is not required for formation of the PPAR-activating molecule, suggesting the active ligand is a fatty acid, its CoA ester, or a derivative prior to beta-oxidation.\",\n      \"method\": \"Stable CHO cell transcriptional transactivation assay using PPAR-glucocorticoid receptor chimera with MMTV-PLAP reporter; metabolic inhibitor studies\",\n      \"journal\": \"The Journal of steroid biochemistry and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — reconstituted cell-based assay with systematic fatty acid structure-activity, single lab\",\n      \"pmids\": [\"7626496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Human NUC1 (a PPAR subtype, PPARβ/δ) acts as a repressor of hPPARα transcriptional activation; hNUC1 cooperatively binds a PPAR-responsive element with hRXRα and represses hPPARα by titrating out a factor required for activation. Repression is specific (does not affect progesterone or retinoic acid receptors) and is overcome by excess hPPARα.\",\n      \"method\": \"Transient transfection reporter assay, co-operative DNA binding assay, competitive transfection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal functional assays with specificity controls, single lab\",\n      \"pmids\": [\"7876127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PPARα activation downregulates hepatic apolipoprotein C-III gene expression and increases lipoprotein lipase gene expression, providing the molecular basis for fibrate-induced triglyceride lowering. PPARα also induces apolipoprotein A-I and A-II expression in humans to raise HDL cholesterol.\",\n      \"method\": \"Gene expression assays in hepatic and other cell systems; fibrate treatment studies\",\n      \"journal\": \"Clinical chemistry and laboratory medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gene regulation demonstrated across multiple target genes, replicated in multiple studies referenced\",\n      \"pmids\": [\"10774955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PPARα negatively interferes with inflammatory gene expression by upregulating the cytoplasmic inhibitor IκBα, establishing an autoregulatory loop with NF-κB. This induction occurs in the absence of a PPRE but requires NF-κB and Sp1 elements in the IκBα promoter and DRIP250 cofactors.\",\n      \"method\": \"Promoter reporter assays, cofactor requirement analysis\",\n      \"journal\": \"Advances in experimental medicine and biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter analysis with defined element requirements, single lab but multiple methods described\",\n      \"pmids\": [\"14713228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Ppara knockout mice and siRNA-mediated hepatic Ppara knockdown produce comparable transcriptional profiles and metabolic phenotypes (hypoglycemia, hypertriglyceridemia), validating that these phenotypes are specifically due to loss of PPARα function in the liver. Combined with fenofibrate agonist profiles, candidate genes proximal to PPARα regulation were identified.\",\n      \"method\": \"Genetic knockout comparison, hydrodynamic siRNA delivery, transcriptional profiling, metabolic phenotyping\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO and RNAi knockdown with identical phenotypes, multiple orthogonal methods\",\n      \"pmids\": [\"16945951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"AMPK activators (AICAR and metformin) inhibit PPARα (and PPARγ) transcriptional activity in hepatoma cells; this inhibition does not affect PPAR/RXR binding to DNA and does not depend on AMPK kinase activity but rather on the activated conformation of AMPK.\",\n      \"method\": \"Transfection with PPRE luciferase reporter, AMPK activator/inhibitor treatment, EMSA for DNA binding, nuclear localization studies\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (reporter assay, DNA binding, dominant-negative/constitutively active constructs), single lab\",\n      \"pmids\": [\"21700905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PPARα (PPARA) transcriptionally regulates CYP3A4 expression in human liver; shRNA-mediated PPARA knockdown in primary human hepatocytes decreased CYP3A4 mRNA by more than 50%, and PPARA SNP rs4253728 associates with reduced PPAR-α protein and reduced CYP3A4 activity in a human liver bank.\",\n      \"method\": \"shRNA knockdown in primary human hepatocytes, candidate-gene association in human liver bank, pharmacokinetic validation in atorvastatin-treated volunteers\",\n      \"journal\": \"Clinical pharmacology and therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional knockdown in primary cells plus human genetic validation and pharmacokinetic confirmation, multiple orthogonal methods\",\n      \"pmids\": [\"22510778\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Krüppel-like factor 5 (KLF5) activates Ppara gene expression via direct binding to the Ppara promoter in cardiac myocytes; this is blocked in septic mouse hearts by c-Jun, which binds an overlapping promoter site. Cardiac-specific Klf5 knockout mice show reduced Ppara expression, reduced fatty acid oxidation, decreased ATP, increased triglyceride accumulation, and cardiac dysfunction.\",\n      \"method\": \"Promoter binding assay (direct binding), cardiac-specific conditional knockout mice, metabolic flux measurements, echocardiography\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct promoter binding demonstrated, conditional KO with defined metabolic and functional phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"26574507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Hepatocyte-specific PPARA is exclusively responsible for agonist-induced hepatocyte proliferation; macrophage PPARA does not contribute to proliferation but is required for downregulation of inflammatory cytokines IL-15 and IL-18 in response to PPARA agonism.\",\n      \"method\": \"Hepatocyte-specific and macrophage-specific conditional Ppara knockout mice, Wy-14643 agonist treatment, BrdU labeling, gene expression analysis, primary cell studies\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional knockouts with defined phenotypic readouts, multiple orthogonal methods\",\n      \"pmids\": [\"28082284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Pharmacological activation of PPARA by agonists gemfibrozil or Wy14643 induces autophagy in human microglia and glioma cells in a PPARA-dependent manner (shown by siRNA knockdown), leading to enhanced autophagosome biogenesis, reduced soluble and insoluble Aβ, and reversal of memory deficits in APP-PSEN1ΔE9 mice.\",\n      \"method\": \"PPARA agonist treatment, siRNA knockdown, autophagy marker analysis (LC3B, SQSTM1), ELISA for Aβ, behavioral testing in transgenic mice\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic (siRNA) approaches, multiple readouts, single lab\",\n      \"pmids\": [\"30898012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PPARA activation facilitates primary ciliogenesis by promoting autophagy; pharmacological or genetic inactivation of autophagy blocks PPARA-induced ciliogenesis. Conversely, NR1H4/FXR activation represses cilia formation. In ppara-/- mice, starvation-induced ciliogenesis is impaired due to defective autophagy, and kidneys show ciliopathy-like damage.\",\n      \"method\": \"PPARA agonist/antagonist treatment, ppara-/- mice, genetic autophagy knockdown, rapamycin rescue, NR1H4 knockdown, in vivo starvation studies\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO mouse model plus pharmacological and genetic manipulation in vitro with multiple orthogonal readouts, in vivo validation\",\n      \"pmids\": [\"29771182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Lysosomal inhibition downregulates PPARA and its coactivator PPARGC1A/PGC1α at the transcriptional level, suppressing peroxisomal gene expression; ectopic induction of PPARA transcriptional activity rescues peroxisomal gene expression after lysosomal inhibition.\",\n      \"method\": \"Bafilomycin A1 treatment, TFEB knockdown, microarray and qPCR, PPARA overexpression rescue in AML12 hepatocyte cell line\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic manipulation with rescue experiment, single lab\",\n      \"pmids\": [\"31032705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PPARα directly upregulates the long non-coding RNA gene Gm15441 through PPARα binding sites within its promoter; Gm15441 expression suppresses its antisense transcript encoding TXNIP, which in turn decreases TXNIP-stimulated NLRP3 inflammasome activation, CASP1 cleavage, and IL1B maturation. Gm15441-null mice show elevated NLRP3 inflammasome activation in response to PPARα agonism and fasting.\",\n      \"method\": \"ChIP for PPARα binding sites, Gm15441-null mouse generation, inflammasome activation assays, CASP1/IL1B cleavage analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct PPARα binding at promoter demonstrated by ChIP, genetic null mouse validation, multiple pathway readouts\",\n      \"pmids\": [\"33203882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PPARA activation promotes hepatocyte proliferation via an epigenetic mechanism: PPARA induces E2F8 expression (a newly identified PPARA target gene), which upregulates UHRF1, which then methylates the Cdh1 promoter (marked with H3K9me3) to repress CDH1 expression and activate Wnt/Myc signaling driving hyperproliferation.\",\n      \"method\": \"PPARA agonist treatment, PPARA-deficient mice, E2F8/UHRF1 knockdown, ChIP for H3K9me3 at Cdh1 promoter, CDH1 forced expression, Wnt target gene analysis\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic interventions, ChIP demonstrating epigenetic mark, rescue/forced expression experiments establishing pathway order\",\n      \"pmids\": [\"35479397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-141 suppresses HBV replication by targeting PPARA at the post-transcriptional level; siRNA knockdown of PPARA inhibits HBV replication similarly to miR-141, and the mechanism involves interference with HBV promoter function through reduced PPARA activity.\",\n      \"method\": \"miRNA mimic transfection, siRNA knockdown of PPARA, luciferase promoter reporter assay, HBV replication quantification in HepG2 cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA and miRNA mimic with promoter reporter validation, single lab\",\n      \"pmids\": [\"22479552\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MIR20B specifically targets PPARA mRNA, reducing fatty acid oxidation and mitochondrial biogenesis in hepatocytes; MIR20B overexpression increases hepatic lipid accumulation and suppresses the therapeutic effect of fenofibrate (PPARα agonist) in NAFLD mouse models, while anti-MIR20B improves FA oxidation and insulin sensitivity.\",\n      \"method\": \"miRNA regulatory network analysis, MIR20B mimic/anti-MIR20B in HepG2, Huh-7, primary hepatocytes and HFD/MCD mice, luciferase reporter, FA oxidation assay, mitochondrial biogenesis measurement\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — validated in multiple cell types and in vivo mouse models with mechanistic rescue experiments, multiple orthogonal methods\",\n      \"pmids\": [\"34964438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PPARA-null mice develop age-related hepatic steatosis, with reductions in glucose and glycogen in liver and muscle and profound changes in lipid metabolism across tissues, demonstrating that PPARA is required for normal fatty acid and glucose homeostasis in liver, heart, skeletal muscle, and adipose tissue.\",\n      \"method\": \"1H NMR spectroscopy and GC-MS metabolomics in Ppara-null vs wild-type mice across aging (3–13 months), multivariate statistics\",\n      \"journal\": \"Molecular systems biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — metabolomic profiling of genetic KO across multiple tissues and timepoints, single study\",\n      \"pmids\": [\"19357638\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PPARα (PPARA) is a ligand-activated nuclear receptor transcription factor that heterodimerizes with RXR to bind peroxisome proliferator response elements (PPREs) and directly regulate genes governing fatty acid uptake, beta-oxidation, lipoprotein metabolism (ApoA-I, ApoA-II, ApoC-III, LPL), and peroxisomal/mitochondrial lipid catabolism; it suppresses hepatic inflammation via IκBα upregulation, promotes autophagy to drive ciliogenesis and Aβ clearance, induces hepatocyte proliferation through an E2F8-UHRF1-CDH1 epigenetic axis, regulates CYP3A4 expression in hepatocytes, and is transcriptionally controlled by upstream factors including KLF5 (activator) and c-Jun (repressor) at its promoter, as well as post-transcriptionally by miRNAs (miR-141, miR-20b), while its activity is inhibited by AMPK in a kinase-activity-independent manner.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PPARα (PPARA) is a ligand-activated nuclear receptor that heterodimerizes with retinoid X receptor (RXR) and binds peroxisome proliferator response elements (PPREs) upstream of target genes to drive transcription, with fatty acids and their derivatives serving as direct activating ligands [#0, #1]. Through this activity it is the master transcriptional regulator of hepatic and systemic lipid handling: it lowers triglycerides by repressing apolipoprotein C-III and inducing lipoprotein lipase, raises HDL via ApoA-I/ApoA-II induction [#3], and is required for normal fatty acid and glucose homeostasis across liver, heart, muscle, and adipose tissue, with loss producing hepatic steatosis, hypoglycemia, and hypertriglyceridemia [#5, #17]. PPARα additionally restrains inflammation through PPRE-independent transcriptional outputs, upregulating IκBα to form an autoregulatory loop with NF-κB [#4] and inducing the lncRNA Gm15441 to suppress TXNIP-driven NLRP3 inflammasome activation [#13]. It promotes autophagy, which underlies PPARα-dependent primary ciliogenesis and Aβ clearance [#11, #10], and it drives hepatocyte proliferation in a hepatocyte-autonomous manner through an E2F8–UHRF1–CDH1 epigenetic axis activating Wnt/Myc signaling [#9, #14]. In human liver it also regulates CYP3A4 expression [#7]. PPARA expression and activity are controlled by upstream transcription factors KLF5 (activator) and c-Jun (repressor) at its promoter [#8], by miRNAs miR-141 and miR-20b post-transcriptionally [#15, #16], and its transactivation is inhibited by activated AMPK independently of AMPK kinase activity and without altering DNA binding [#6].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established the core molecular machinery: how PPARα converts a signal into transcription by defining its DNA target, dimerization partner, and the nature of its activating ligand.\",\n      \"evidence\": \"Transactivation and DNA-binding assays showing RXR heterodimerization at PPREs; CHO chimera reporter assays mapping fatty-acid structure-activity\",\n      \"pmids\": [\"8538617\", \"7626496\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous physiological ligand identity not resolved\", \"Co-activator/co-repressor recruitment not detailed\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Showed PPARα activity is constrained by competition within the receptor family, identifying NUC1 (PPARβ/δ) as a repressor titrating a shared limiting factor.\",\n      \"evidence\": \"Transient transfection reporter and cooperative DNA-binding assays with receptor specificity controls\",\n      \"pmids\": [\"7876127\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the titrated activating factor not determined\", \"In vivo relevance of the repression not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Connected PPARα transcriptional outputs to clinically relevant lipoprotein metabolism, providing the mechanistic basis for fibrate triglyceride lowering and HDL raising.\",\n      \"evidence\": \"Gene expression assays for ApoC-III, LPL, ApoA-I/A-II under fibrate treatment in hepatic systems\",\n      \"pmids\": [\"10774955\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect regulation of each target not fully dissected\", \"Human in vivo confirmation limited\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined a PPRE-independent anti-inflammatory mechanism, showing PPARα enforces an autoregulatory brake on NF-κB via IκBα induction.\",\n      \"evidence\": \"Promoter reporter assays with NF-κB/Sp1 element and DRIP250 cofactor requirement analysis\",\n      \"pmids\": [\"14713228\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of cofactor-dependent activation without a PPRE unclear\", \"Single-lab promoter analysis\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Validated that hepatic loss-of-function phenotypes are specifically attributable to PPARα, distinguishing on-target effects from genetic compensation.\",\n      \"evidence\": \"Comparison of Ppara knockout vs hepatic siRNA knockdown with transcriptional profiling and metabolic phenotyping\",\n      \"pmids\": [\"16945951\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct target genes not separated from secondary responses\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified an unexpected non-canonical inhibition of PPARα by AMPK acting through its activated conformation rather than kinase activity.\",\n      \"evidence\": \"PPRE luciferase reporter, EMSA, and dominant-negative/constitutively active AMPK constructs in hepatoma cells\",\n      \"pmids\": [\"21700905\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physical basis of conformation-dependent inhibition not resolved\", \"In vivo significance untested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated PPARα is required systemically for lipid and glucose homeostasis across multiple tissues, not just liver.\",\n      \"evidence\": \"1H NMR and GC-MS metabolomics in Ppara-null vs wild-type mice across aging and tissues\",\n      \"pmids\": [\"19357638\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Tissue-specific contributions not separated\", \"Causal target genes not identified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extended PPARα function into xenobiotic metabolism and provided human genetic validation of its control of CYP3A4.\",\n      \"evidence\": \"shRNA knockdown in primary human hepatocytes, SNP association in a liver bank, and pharmacokinetic confirmation in volunteers\",\n      \"pmids\": [\"22510778\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding at CYP3A4 regulatory regions not shown\", \"Mechanism of SNP effect on protein level unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed PPARA is a post-transcriptional target whose suppression affects viral biology, linking miR-141-mediated PPARA reduction to HBV replication control.\",\n      \"evidence\": \"miRNA mimic and PPARA siRNA with luciferase promoter reporter and HBV replication quantification in HepG2\",\n      \"pmids\": [\"22479552\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which PPARA supports HBV promoter function not defined\", \"In vivo relevance untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified the upstream transcriptional control of PPARA itself, with KLF5 activating and c-Jun repressing the promoter to govern cardiac fatty acid oxidation.\",\n      \"evidence\": \"Direct promoter binding assays, cardiac-specific Klf5 conditional knockout, metabolic flux and echocardiography\",\n      \"pmids\": [\"26574507\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generalization beyond cardiomyocytes not established\", \"Other promoter regulators not mapped\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Dissected cell-type-specific PPARα roles, showing hepatocyte PPARα drives proliferation while macrophage PPARα controls inflammatory cytokine suppression.\",\n      \"evidence\": \"Hepatocyte- and macrophage-specific conditional Ppara knockouts with Wy-14643, BrdU labeling and cytokine analysis\",\n      \"pmids\": [\"28082284\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mediators of proliferation not yet defined at this stage\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked PPARα to autophagy-dependent organelle biogenesis, establishing that PPARα-driven autophagy is required for primary ciliogenesis.\",\n      \"evidence\": \"PPARA agonist/antagonist, ppara-/- mice, autophagy knockdown, rapamycin rescue, and starvation studies\",\n      \"pmids\": [\"29771182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct autophagy gene targets of PPARα not enumerated\", \"Mechanism opposing FXR repression unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Generalized PPARα-driven autophagy to neurodegeneration, showing agonist-induced autophagy enhances Aβ clearance and reverses memory deficits.\",\n      \"evidence\": \"Agonist treatment with siRNA knockdown, autophagy markers, Aβ ELISA, and behavior in APP-PSEN1ΔE9 mice\",\n      \"pmids\": [\"30898012\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets driving autophagosome biogenesis unspecified\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed a lysosome-to-nucleus feedback whereby lysosomal function sustains PPARA/PGC1α transcription to maintain peroxisomal gene expression.\",\n      \"evidence\": \"Bafilomycin A1, TFEB knockdown, microarray/qPCR, and PPARA overexpression rescue in AML12 cells\",\n      \"pmids\": [\"31032705\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which lysosomal status controls PPARA transcription unclear\", \"In vivo confirmation lacking\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined a direct PPARα-driven lncRNA circuit (Gm15441) that restrains the TXNIP–NLRP3 inflammasome during agonism and fasting.\",\n      \"evidence\": \"ChIP for PPARα binding sites, Gm15441-null mice, and inflammasome/CASP1/IL1B readouts\",\n      \"pmids\": [\"33203882\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human orthologous lncRNA mechanism not addressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established MIR20B as a post-transcriptional repressor of PPARA controlling hepatic fatty acid oxidation and fibrate response in NAFLD.\",\n      \"evidence\": \"MIR20B mimic/anti-MIR20B in multiple hepatocyte lines and HFD/MCD mice, luciferase reporter, FA oxidation and mitochondrial biogenesis assays\",\n      \"pmids\": [\"34964438\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay with other PPARA-targeting miRNAs not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Resolved the molecular mediators of hepatocyte proliferation, defining the E2F8–UHRF1–CDH1 epigenetic axis downstream of PPARα.\",\n      \"evidence\": \"Agonist treatment, PPARA-deficient mice, E2F8/UHRF1 knockdown, ChIP for H3K9me3 at Cdh1, CDH1 forced expression, Wnt target analysis\",\n      \"pmids\": [\"35479397\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect PPARα regulation of E2F8 not fully shown\", \"Relevance to human hepatocarcinogenesis untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The endogenous physiological ligand of PPARα and the structural basis of its non-canonical regulation (AMPK conformation, PPRE-independent transactivation) remain undefined.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No defined endogenous activating ligand\", \"No structural model linking AMPK conformation to PPARα inhibition\", \"Cofactor logic of PPRE-independent gene induction unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 3, 13, 14]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 13]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 5, 16, 17]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 13, 14]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 13, 9]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [10, 11, 12]}\n    ],\n    \"complexes\": [\"PPARα-RXR heterodimer\"],\n    \"partners\": [\"RXR\", \"KLF5\", \"JUN\", \"PPARGC1A\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}